CD4 and liver cancer: The experimental results showed that compared with healthy volunteers, the proportion of Treg in peripheral blood of liver cancer patients in CD4+ T cells was analyzed and cell surface markers were detected on flow cytometry, and the number of Treg in the liver cancer group was higher than that in the control group (P < 0.01, Figure 1(a)).